Identification and validation of an explainable prediction model of favorable outcome under integrative medicine treatment exposure in DKD adult patients: a retrospective cohort study - Report - MDSpire

Identification and validation of an explainable prediction model of favorable outcome under integrative medicine treatment exposure in DKD adult patients: a retrospective cohort study

  • By

  • Li Jiang

  • Haojun Zhang

  • Yanmei Wang

  • Meihua Yan

  • Xiai Wu

  • July 16, 2026

Share

Clinical Report: Predictive Model for Favorable Outcomes in Adult DKD Patients

Overview

This study developed and validated a predictive model for favorable outcomes in adult patients with diabetic kidney disease (DKD) undergoing integrative medicine treatment (IMT). Utilizing a cohort of 7,400 patients, the model demonstrated an area under the curve (AUC) of 0.783 in training and 0.762 in validation.

Background

Diabetic kidney disease (DKD) affects a significant portion of adults with diabetes and is a leading cause of end-stage kidney disease. Current predictive models often lack the specificity needed to guide treatment decisions effectively.

Data Highlights

ModelAUCTraining SetTest SetValidation Set
XGBoost0.7830.7150.762

Key Findings

  • XGBoost classifier was the most effective model with an AUC of 0.783 in the training set.
  • The model identified 10 key variables influencing outcomes: creatinine, uric acid, age, red blood cell count, urea, glucose, platelet count, calcium, white blood cell count, and sodium.
  • The model was validated using a temporal cohort of 3,500 patients.
  • The predictive model was deployed as an interactive web application for real-time predictions.

Clinical Implications

The developed predictive model can assist clinicians in identifying DKD patients who are likely to benefit from integrative medicine treatment. This approach may enhance personalized treatment strategies and improve patient outcomes in DKD management.

Conclusion

The predictive model for favorable outcomes under IMT exposure in DKD patients has been validated and is available for real-time application.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. Author(s)/Org, Source, Year -- Title
  3. Author(s)/Org, Source, Year -- Title
  4. Author(s)/Org, Source, Year -- Title
  5. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 | Diabetes Care | American Diabetes Association
  6. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes | New England Journal of Medicine
  7. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 | Diabetes Care | American Diabetes Association
  8. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes | New England Journal of Medicine
  9. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1327030/pdf

Original Source(s)

Related Content